Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
7
Bullish
4
Bearish
11
Neutral
7
Bullish
28
Bearish
8
Neutral
0
Bullish
24
Discovery themes featuring this stock
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability.
Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products.
Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,13,884 Cr
Low Risk
29.4
35.0
1.5
3.3
1,672.20
1,165.55
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4457.15 | 1,50,850 Cr | 66.40 | 17.85 | 0.13 | 25.33 | 27.37 | 14.64 | ||
1361.00 | 1,13,884 Cr | 29.36 | 3.31 | 0.92 | 11.27 | 14.95 | 9.11 | ||
1307.00 | 1,11,339 Cr | 26.53 | 2.94 | 0.60 | 11.07 | 12.54 | 7.15 | ||
2326.80 | 1,04,542 Cr | 19.60 | 4.66 | 0.79 | 23.76 | 24.88 | 13.96 | ||
2507.00 | 1,02,964 Cr | 57.87 | 6.74 | 0.00 | 11.45 | 12.34 | 6.26 | ||
864.25 | 1,02,530 Cr | 20.76 | 4.05 | 0.10 | 19.44 | 19.08 | 10.52 | ||
1415.00 | 87,861 Cr | 25.20 | 2.51 | 0.00 | 9.77 | 12.69 | 6.63 | ||
| Median: 7 Co. | — | 1415.00 | 1,04,542 Cr | 26.53 | 4.05 | 0.13 | 11.45 | 14.95 | 9.11 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Cipla Ltd (CIPLA) is currently trading at 1,401.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.55 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cipla Ltd has a market capitalization of approximately 1,13,883.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,13,883.72 Cr, Cipla Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cipla Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cipla Ltd is 29.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The move was driven by largely positive brokerage commentary that highlighted India’s 15% growth, pipeline visibility, and expectations of improved US launches and earnings visibility.
The stock reacted to management’s FY27 guidance, including 18%-20% EBITDA margin guidance, expectations of double-digit India revenue growth, and a higher US sales run-rate target by end-FY27.
Cipla said it plans to add one to two biosimilars annually over the next five to six years and is expanding both owned and partnered biosimilars programs for the US.
The provided material cites pricing pressure and commoditisation in traditional generics, prompting Cipla to prioritise differentiated respiratory products, chronic therapies, specialty medicines and complex generics.
Earnings Transcript
Cipla's Q4 FY26 call reports One India revenues >INR12,500 Cr and 15% YoY Q4 growth, North America Q4 revenue of $155m (FY $780m), US Ventolin approval, multiple product launches, Lilly and Mannkind partnerships and portfolio expansions.
Earnings Call Transcript
Cipla filed the transcript of its Q4 FY26 earnings call (13 May 2026); management highlighted One India revenues >INR12,500cr, One India Q4 growth 15% YoY, North America Q4 revenue USD155m (FY $780m), product launches, partnerships and strategic milestones.
Audited financial results
Cipla Limited announced audited standalone and consolidated financial results for the quarter and financial year ended 31 Mar 2026, approved by the Board on 13 May 2026; auditors Walker Chandiok & Co LLP; results posted on company and exchange websites.
